balstilimab,botensilimab
agenus
 impact of next gen ctla4i botensilimab in mss metastatic crc is promising.
bot/bal led to 24% orr (10/41 patients), 73% of disease control, median dor not reached. in patients without liver mets, orr 42 % ! 
GI Oncologist. Phase 1. Pancreatic cancer researcher @BIDMCHealth. Assist Prof @HarvardMed Alum @UFRJ. Opinions are mine.